박셀바이오

323990KOSDAQ

56.8 / 100

Reference Date: 2026-09-08

Financial Score17.5 / 40

News Sentiment18.3 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 5.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Parkcell Bio is a biotech company specializing in cancer immunotherapy, developing various platforms such as Vax-NK and Vax-CAR for immune cell therapies and targeted anticancer drugs. It also expands its pet healthcare business through its veterinary immunomodulatory drug 'Vaxleukin-15' and has enhanced its commercialization capabilities by constructing an advanced manufacturing platform following the completion of its new headquarters in 2025.

Number of Employees

91people

Average Salary

49.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.67Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-20.04Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

3.69Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲7004.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼16.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -17.7% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 1Negative 0Average Sentiment Score 73.3

Positive
메타이뮨텍, 반려동물 면역분석 ‘CPI’ 상용화 시동… 박셀바이오에.....
박셀바이오는 메타이뮨텍의 원천기술 LSIT를 활용한 반려동물 면역분석 상용화로 인해 항암면역치료 모니터링 분야에서의 혁신적 기회를 확보했다.
Neutral
금융서 쌓은 '데이터 DNA' 이식…아이티아이즈, AI 신약 플랫폼 새...
아이티아이즈의 AI 기술 활용 계획 발표로 인해 관련 산업 전반에 대한 관심 증가, 하지만 박셀바이오와 직접적인 연관성은 확인되지 않음.
Positive
박셀바이오, NK세포 기반 간암 치료기술 대만 특허 등록
박셀바이오의 NK세포 기반 간암 치료기술이 대만에서 특허 등록되어 기술 경쟁력과 시장 확장 가능성이 높아졌다.

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 4,400Won52-week high 11,00052-week low 3,585

1-month return4.0Point

1m +5.52% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14